The canonical GHRH + GHRP pair — how each works alone, why they are almost always studied together, and what the no-DAC distinction means.
CJC-1295 and Ipamorelin work on different receptors that converge on the same outcome: a stronger, cleaner growth-hormone pulse. CJC-1295 hits the GHRH receptor; Ipamorelin hits the ghrelin receptor.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | GHRP / ghrelin receptor agonist |
| Receptor | GHRH-R | GHS-R1a (ghrelin) |
| Sequence length | 30 amino acids | 5 amino acids |
| Half-life (no-DAC) | ~30 minutes | ~2 hours |
| Cortisol / prolactin effect | Minimal | Minimal (selectivity is its hallmark) |
| Best used | Paired with a GHRP | Paired with a GHRH analog |
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH). The no-DAC version produces a pulsatile GH release pattern and is frequently paired with a ghrelin-receptor peptide such as Ipamorelin in research protocols.
Binds the GHRH receptor on the pituitary to stimulate endogenous growth hormone release while preserving natural pulsatility.
Ipamorelin is a pentapeptide growth hormone secretagogue. It is valued in research for its selectivity — stimulating GH release with minimal effect on cortisol or prolactin in published studies.
Selective ghrelin/GHS-R1a receptor agonist that triggers GH release from the anterior pituitary.
Studied together, the two peptides produce a larger GH pulse than either alone — which is why the pair shows up in nearly every modern GH-support research protocol.
The table above compares published characteristics, not outcomes for any individual. Mechanism, half-life, and dosing cadence are properties of the molecule; response, tolerability, and suitability are properties of the person. Trial averages describe populations and say nothing definitive about a single case.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
They act on complementary pathways — CJC-1295 on the GHRH receptor and Ipamorelin on the ghrelin/GHS-R receptor — producing a stronger synergistic GH pulse in research models.
DAC (Drug Affinity Complex) extends half-life to several days for tonic GH elevation. No-DAC preserves natural pulsatility, which most research protocols prefer.
No. Ipamorelin is a peptide secretagogue that supports endogenous GH release; it is not an anabolic steroid.
Published research shows Ipamorelin is unusually clean on cortisol and prolactin compared to older GHRPs — a major reason it's preferred in modern protocols.